

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

### **保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1246)**

### **PROFIT WARNING**

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the financial year ended 31 March 2022 (the “**Year**”), the Group is expected to record a consolidated net loss of not less than approximately HK\$790 million for the Year, as compared with the consolidated net loss of approximately HK\$175 million for the year ended 31 March 2021. Such expected substantial consolidated net loss for the Year was mainly due to the following factors:

- (i) the expected fair value loss on investment properties of approximately HK\$592 million for the Year (2021: approximately HK\$4 million) and expected impairment loss on property, plant and equipment of approximately HK\$61 million for the Year (2021: reversal of impairment loss of approximately HK\$5 million) due to the adverse impact caused by the outbreak of COVID-19 pandemic and the weakened demand of potential home-buying customers due to deterioration of their overall financial condition brought by the uncertain global macro-economic environment; and
- (ii) the increase in income tax and land appreciation tax of approximately HK\$28 million provided for the Year (2021: income tax credit of approximately HK\$5 million) as a result of the increase in delivery of properties.

The Company is still in the process of finalising the annual results of the Group for the Year. The information contained in this announcement is only based on preliminary assessment made by the Board with reference to the unaudited consolidated management accounts of the Group for the Year

and other information currently available to the Board, which have not been audited by the Company's auditors nor reviewed by the audit committee of the Company. The annual results of the Group for the Year may be subject to adjustments, if any, upon further review.

Shareholders and potential investors are advised to read carefully the unaudited annual results announcement and audited annual results announcement of the Group for the Year for further details, which are expected to be published on or about 30 June 2022 and 29 July 2022, respectively.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**Dai Dong Xing**  
*Executive Director and Chairman*

Hong Kong, 22 June 2022

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.*

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*